Perceptive Advisors LLC Buys New Position in Neumora Therapeutics, Inc. $NMRA

Perceptive Advisors LLC bought a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,104,097 shares of the company’s stock, valued at approximately $9,953,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Siren L.L.C. increased its position in Neumora Therapeutics by 35.1% during the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after purchasing an additional 2,209,039 shares during the period. Millennium Management LLC lifted its position in shares of Neumora Therapeutics by 80.1% in the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock worth $6,474,000 after purchasing an additional 1,608,266 shares during the period. Renaissance Technologies LLC lifted its position in shares of Neumora Therapeutics by 24.2% in the 4th quarter. Renaissance Technologies LLC now owns 1,445,902 shares of the company’s stock worth $2,588,000 after purchasing an additional 281,926 shares during the period. Ikarian Capital LLC boosted its stake in shares of Neumora Therapeutics by 10,128.9% during the 4th quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after purchasing an additional 1,265,910 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Neumora Therapeutics by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 1,003,746 shares of the company’s stock valued at $1,797,000 after purchasing an additional 34,818 shares in the last quarter. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Analyst Ratings Changes

NMRA has been the subject of a number of research reports. Mizuho decreased their price target on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research note on Thursday, June 18th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Friday, July 17th. Wall Street Zen downgraded Neumora Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, July 25th. Royal Bank Of Canada decreased their target price on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Finally, Needham & Company LLC lowered their target price on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $6.57.

Neumora Therapeutics Stock Down 2.4%

NASDAQ:NMRA opened at $1.61 on Friday. The firm’s 50-day moving average price is $1.64 and its 200-day moving average price is $2.15. The company has a market capitalization of $298.30 million, a PE ratio of -1.21 and a beta of 2.74. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.09 and a quick ratio of 5.09. Neumora Therapeutics, Inc. has a 1-year low of $0.83 and a 1-year high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, equities analysts predict that Neumora Therapeutics, Inc. will post -0.93 EPS for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.